Figures & data
![Figure 5. Schematic model of the mechanism involved in the antitumor effect of vaccination with complexes consisting of ECDHER2 and anti-HER2/neu IgG3-(IL-2) in DC. Anti-HER2/neu IgG3-(IL-2) can bind HER2/neu expressed as soluble antigen ECDHER2. This soluble antigen is poorly processed because of its high level of glycosylation that results in its binding to the mannose receptor, early endosomal retention, and recycling back to the cell surface. However, the interaction between the complex of ECDHER2 plus anti-HER2/neu IgG3-(IL-2) with IL-2 receptor (IL-2R) expressed on the cell surface induces ECDHER2 internalization and trafficking to the late endosome/lysosome MHC class II pathway facilitating the processing and presentation to CD4+ T cells via MHC class II molecules in order to stimulate the immune response against HER2/neu positive tumor cells.](/cms/asset/4a37a13d-e697-4fe4-b8e3-dbf441e7ce23/iebt_a_11196345_f0001_b.jpg)
Register now or learn more
Free access
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.